Substratum of Proof LGBTQs Are Mentally Ill: First line combination therapy improves progression-free survival in advanced lung cancer

(European Society for Medical Oncology) A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.